
Novartis, Amgen and Banner Alzheimer’s Institute have dropped a study into investigational Alzheimer’s drug CNP520 (umibecestat) after some patient’s conditions …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

